ArticleCardiology research2025
Lipid-Lowering Therapy in Post-Acute Coronary Syndrome Patients: An Observational Study.
Article in Cardiology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Statin intensity, prescribing patterns, and LDL‑C reduction following ACS and in CCD patients who underwent PCI in a tertiary care setting.BMC cardiovascular disorders · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease remains a major cause of morbidity and mortality globally. International guidelines recommend aggressive lipid-lowering therapy (LLT) in patients with atherosclerotic cardiovascular disease (ASCVD), targeting a low-density lipoprotein cholesterol (LDL-C) level of < 55 mg/dL and a ≥ 50% reduction from baseline. However, real-world studies continue to show suboptimal LDL-C target achievement. This study aimed to assess the proportion of post-acute coronary syndrome (ACS) patients achieving both LDL-C < 55 mg/dL and a ≥ 50% reduction from baseline at 6 months. A secondary objective was to evaluate target achievement after 1 year and analyze outcomes across different LLT regimens. Methods: We conducted a retrospective cohort study at a single tertiary center, including patients aged ≥ 18 years who presented with ACS between January 2021 and January 2022, underwent percutaneous coronary intervention (PCI), and had documented LDL-C levels at baseline and at least one follow-up within 12 months. Patients with baseline LDL-C ≤ 55 mg/dL or on ongoing LLT were excluded. Results: A total of 122 patients were included (mean age 63.5 years; 59.8% had both diabetes and hypertension). At 6 months, only 13/82 patients (15.9%) achieved the primary LDL-C target. The highest achievement was seen in the rosuvastatin + ezetimibe group (30.0%), followed by rosuvastatin (17.9%), atorvastatin + ezetimibe (14.3%), and atorvastatin monotherapy (14.0%). A ≥ 50% LDL-C reduction without meeting the < 55 mg/dL threshold was observed in 24/82 patients (29.3%). Conclusions: LDL-C target achievement remains low among post-ACS patients despite high-intensity statin use. Combination therapy with rosuvastatin + ezetimibe showed more favorable outcomes, particularly in older adults. These findings underscore the need for structured follow-up, treatment intensification, and broader use of advanced therapies such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to close the real-world treatment gap.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.